Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | MELK | Q14680 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.43 |
| ▸ | ATR | Q13535 | 3/20 | 0.43 |
| ▸ | PRKDC | P78527 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL387443 | 0.79 | ALOX5AP (0.52) | MAP4K4MINK1TNIKFYNKCNH2 | |
| SCHEMBL388829 | 0.79 | ENPP2 (0.57) | ENPP2MELKMAP4K4MINK1TNIK | |
| SCHEMBL903914 | 0.79 | MAP4K4 (0.54) | ENPP2MELKMAP4K4MINK1TNIK | |
| SCHEMBL903972 | 0.76 | ENPP2 (0.57) | ENPP2MELKMAP4K4MINK1TNIK | |
| SCHEMBL387582 | 0.75 | FEN1 (0.45) | PTGS2 | |
| SCHEMBL4572251 | 0.74 | PTGS2 (0.51) | KCNH2PTGS2ATR | |
| SCHEMBL1642998 | 0.74 | ENPP2 (0.52) | ENPP2MELKMAP4K4MINK1TNIK | |
| SCHEMBL4214238 | 0.72 | CA2 (0.50) | KCNH2PTGS2 | |
| SCHEMBL21770450 | 0.72 | PTGS2 (0.54) | FYNKCNH2PTGS2RORC | |
| SCHEMBL29129729 | 0.72 | ENPP2 (0.61) | ENPP2MAP4K4MINK1TNIKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102731492-B | Cyclohexanes derivant, its preparation method and in application pharmaceutically | 江苏恒瑞医药股份有限公司 | 2016-06-29 | — | — | CN | disclosed |
| CN-102639500-B | Tricyclic compound, preparation method and pharmaceutical use thereof | SHANGHAI HENGRUI PHARM CO LTD | 2015-02-11 | — | — | CN | disclosed |
| CN-102731492-A | Cyclohexane derivative, its preparation method and its application in medicines | JIANGSU HENGRUI MEDICINE CO | 2012-10-17 | — | — | CN | disclosed |
| CN-102432598-A | Tricyclic compound, preparation method thereof and pharmaceutical application thereof | JIANGSU HENGRUI MEDICINE CO | 2012-05-02 | — | — | CN | disclosed |
| WO-2012041158-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-04-05 | — | — | WO | disclosed |
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | ENPP2 830/4885MELK 1100/4885MAP4K4 1252/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | ENPP2 830/4885MELK 1100/4885MAP4K4 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.